At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Heparin +1 moredrug
Likely dose
0.9%sodium chloridefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia
In Brief
A Phase 4 clinical trial evaluating Heparin and 0.9%sodium chloride for Covid19 and Pneumonia, Viral. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Randomized, placebo controlled study to determine if nebulized heparin may reduce the need for mechanical ventilation in hospitalized patients with the novel coronavirus, also known as COVID-19. This will be a part of a larger meta-trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Pneumonia, Viral
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartFeb 2021
Primary CompletionAug 2021
TodayJul 2026
First PostedJan 25, 2021
Enrollment StartFeb 22, 2021
Primary CompletionAug 23, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.4 years ago
Interventions
Heparindrug
25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
0.9%sodium chloridedrug
5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization